NRx Pharmaceuticals Secures FDA Labeling Alignment, Plans Final Label This Month
The FDA Office of Generic Drugs provided preliminary alignment on labeling for NRx’s preservative-free ketamine, with only minor formatting change requests and final label submission expected this month. The company now anticipates a GDUFA decision on its abbreviated new drug application in Summer 2026.
1. Preliminary Labeling Alignment
NRx received a letter from the FDA Office of Generic Drugs indicating preliminary agreement on the proposed label for its preservative-free ketamine, with comments limited to minor formatting edits. This step follows a prior determination of bioequivalence and paves the way for final supervisory review of the Abbreviated New Drug Application.
2. Regulatory Timeline
The company plans to submit the revised final label by the end of this month, with the determination remaining preliminary until FDA leadership completes its supervisory review. A final GDUFA decision on approval is expected in Summer 2026 under the Generic Drug User Fee Act.
3. Market Impact and Strategic Importance
Approval of NRx’s preservative-free ketamine could substantially increase U.S. domestic supply amid current backorders from other suppliers. The FDA has designated ketamine a high-priority drug and awarded a National Priority Voucher to encourage re-shoring of its manufacture.
4. Next Steps and Expansion Plans
Alongside the ANDA for NRX-100, NRx is preparing a New Drug Application under Fast Track designation to extend intravenous ketamine use for severe depression with suicidal ideation. The company will continue collaborating with FDA on both labeling and clinical filings.